Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.44 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GRM7 | Q14831 | 4/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29607565 | 1.00 | IDO1 (0.49) | IDO1MAPTCA1CA2KDM4E | |
| SCHEMBL30496747 | 0.98 | IDO1 (0.50) | IDO1MAPTCA1CA2KDM4E | |
| SCHEMBL15883185 | 0.98 | IDO1 (0.50) | IDO1MAPTCA1CA2KDM4E | |
| SCHEMBL29433039 | 0.85 | MTNR1A (0.61) | CA1CA2MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL30496756 | 0.85 | IDO1 (0.44) | IDO1MAPTCA1CA2KDM4E | |
| Hydrochloric Acid SCHEMBL17186296 | 0.85 | IDO1 (0.44) | IDO1MAPTCA1CA2KDM4E | |
| SCHEMBL29433082 | 0.85 | MTNR1A (0.61) | CA1CA2MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL30976015 | 0.84 | IDO1 (0.42) | IDO1MAPTCA1CA2KDM4E | |
| SCHEMBL17186237 | 0.83 | IDO1 (0.45) | IDO1MAPTCA1CA2KDM4E | |
| SCHEMBL18624792 | 0.82 | KDM4E (0.54) | IDO1MAPTCA1CA2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114423759-B | Fused heteroaryl derivatives, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-111848494-B | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-115232124-A | Crystal form of ATX inhibitor and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-114423759-A | Condensed heteroaryl derivative, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2021078227-A1 | FUSED HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2021-04-29 | — | — | WO | disclosed |
| CN-111848494-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2020-10-30 | — | — | CN | disclosed |
| EP-2970254-B1 | IMIDAZO PYRIDINE COMPOUNDS | LILLY CO ELI (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2984091-B1 | DIHYDROPYRIDO PYRIMIDINE COMPOUNDS AS AUTOTAXIN INHIBITORS | LILLY CO ELI (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2943494-B1 | PYRIDO- OR PYRROLO-FUSED PYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS FOR TREATING PAIN | LILLY CO ELI (US) | 2017-02-22 | — | — | EP | disclosed |
| US-9550774-B2 | Dihydropyrido pyrimidine compounds as autotaxin inhibitors | ELI LILLY AND COMPANY (US) | 2017-01-24 | — | — | US | disclosed |
| US-9394317-B2 | Imidazo pyridine compounds | ELI LILLY AND COMPANY (US) | 2016-07-19 | — | — | US | disclosed |
| EP-2984091-A1 | DIHYDROPYRIDO PYRIMIDINE COMPOUNDS AS AUTOTAXIN INHIBITORS | Eli Lilly and Company (US) | 2016-02-17 | — | — | EP | disclosed |
| EP-2970254-A1 | IMIDAZO PYRIDINE COMPOUNDS | Eli Lilly and Company (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150368240-A1 | DIHYDROPYRIDO PYRIMIDINE COMPOUNDS AS AUTOTAXIN INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150368273-A1 | IMIDAZO PYRIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2015-12-24 | — | — | US | disclosed |
| EP-2943494-A1 | PYRIDO- OR PYRROLO-FUSED PYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS FOR TREATING PAIN | Eli Lilly and Company (US) | 2015-11-18 | — | — | EP | disclosed |
| US-8969555-B2 | Bicyclic pyrimidine compounds | ELI LILLY AND COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| WO-2014168824-A1 | DIHYDROPYRIDO PYRIMIDINE COMPOUNDS AS AUTOTAXIN INHIBITORS | ELI LILLY AND COMPANY (US) | 2014-10-16 | — | — | WO | disclosed |
| WO-2014143583-A1 | IMIDAZO PYRIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014110000-A1 | PYRIDO- OR PYRROLO-FUSED PYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 2014-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368273-A1 | IMIDAZO PYRIDINE COMPOUNDS | ENPP2, TPX2, UACA | CA2 24/4885HRH3 1146/4885HDAC8 190/4885 |
| US-20150368240-A1 | DIHYDROPYRIDO PYRIMIDINE COMPOUNDS AS AUTOTAXIN INHIBITORS | ENPP2, NUDT1, DPYD | CA2 511/4885HRH3 1056/4885HDAC8 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.